Clinical trials: Minimal Change Disease
Gastroesophageal Reflux Disease
Minimal Change Esophagitis by i-Scan Endoscopy in Dyspeptic Patients
The purpose of this study to assess efficacy of SE endoscopy in the detection of MCE in dyspeptic patients with or without GERD diagnosed by GerdQ or by endoscopy + PHM and in normal volunteers.
- Trial name
- MCE (NCT01742377)
- Testing
- Patients with GerdQ positive, Patients with GerdQ negative, Normal volunteers
- Where
- Thailand
- Volunteers
- 174 people
- Sponsor
- Prince of Songkla University
Proteinuria
Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria
The primary objective of this study is to assess the impact of proteinuria on the pharmacokinetic (PK) of a single dose of ALXN1720 in participants with proteinuria.
- Trial name
- NCT05314231
- Testing
- ALXN1720
- Where
- 2 sites in South Korea
- Volunteers
- 13 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Metabolic Syndrome
Effects of Arom Digest Slim on Metabolic Profile and Food Behaviour in Overweight Persons
The present study aims to evaluate the efficacy of Arom Digest Slim in facilitating weight reduction along with a series of minimal nutritional interventions.
- Trial name
- NCT03533881
- Testing
- Arom Digest Slim, Nutritional changes
- Where
- Romania
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- SC Aromaarmony SRL
Nephrotic Syndrome in Children, Nephrotic Syndrome, Minimal Change
REduced-dose Steroid PrOtocol for Childhood Nephrotic SyndromE (RESPONSE)
This is a pilot feasibility study for a proposed full-scale randomized controlled trial to evaluate the effectiveness and safety of a reduced-dose oral prednisone (steroids) regimen to treat childhood steroid-sensitive nephrotic…
- Conditions
- Nephrotic Syndrome in Children, Nephrotic Syndrome, Minimal Change, Nephrotic Syndrome, Nephrotic Syndrome，Idiopathic
- Trial name
- RESPONSE (NCT06635720)
- Testing
- Prednisone
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- The Hospital for Sick Children
Knee Osteoarthritis
Responsiveness and Minimal Clinically Important Difference (MCID) of Knee Injury and Osteoarthritis (KOOS-12) in (OA)
Osteoarthritis (OA) is a common and disabling constant Musculoskeletal Disorder that causes significant weight on individual, Health Care Systems, and social economy.
- Trial name
- NCT06901921
- Testing
- PT-intervention
- Where
- Pakistan
- Volunteers
- 60 people
- Sponsor
- Superior University
Kidney Diseases
Global Kidney Patient Trials Network
This is a prospective international multi-centre, observational cohort study of incident and prevalent patients diagnosed with a kidney disease
- Trial name
- GKPTN (NCT04389827)
- Where
- Australia
- Volunteers
- 5,999 people
- Sponsor
- The George Institute
Muscle Weakness, Critical Illness Myopathy
CPAx: Responsiveness and Minimal Clinically Important Difference
Intensive care unit (ICU) acquired weakness is a common complication associated with long-term physical impairments in survivors of a critical illness.
- Conditions
- Muscle Weakness, Critical Illness Myopathy, Critical Illness Polyneuropathy, Critical Illness Polyneuromyopathy
- Trial name
- NCT06419699
- Where
- 3 sites in Australia, Switzerland
- Volunteers
- 120 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Idiopathic Nephrotic Syndrome (INS)
Non-invasive Diagnosis of Idiopathic Nephrotic Syndromes
Renal biopsy (RB) is the reference diagnostic procedure for Idiopathic Nephrotic Syndrome (INS). It is an invasive procedure, particularly risky during the acute phase of nephrotic syndrome when anticoagulation therapy is…
- Trial name
- DNI-SNI (NCT06820866)
- Where
- France
- Volunteers
- 265 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Idiopathic Nephrotic Syndrome, Minimal Change Disease
Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome
This will be an open-label, randomized controlled trial which compares continued treatment with high dose prednisone (standard therapy) to treatment with rituximab in patients with minimal change disease or focal segmental…
- Conditions
- Idiopathic Nephrotic Syndrome, Minimal Change Disease, Focal Segmental Glomerulosclerosis
- Trial name
- NCT03298698
- Testing
- Rituximab, Prednisone
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Radboud University Medical Center
Multiple Myeloma
MInimal Residual Disease Adapted Strategy
IFM 2020-02 will enroll patients eligible for ASCT less than 66 years. All patients will receive induction based on 6 cycles (28-day) of KRD-Isatuximab (Isa-KRD), in order to achieve deep responses and high MRD negativity rates.
- Trial name
- MIDAS (NCT04934475)
- Testing
- Isatuximab, ASCT
- Where
- 73 sites in Belgium, France and 1 more
- Volunteers
- 791 people
- Sponsor
- Intergroupe Francophone du Myelome
Nurse's Role, Infection
Nurse Leadership for Hospital Infection Control
The aim is to deliver an intervention to promote nurse leadership and decision-making in the hospital setting, by providing them with training for maintaining minimum service delivery standards for hospital infection control with…
- Trial name
- NCT04603079
- Testing
- Intervention for COVID-19 preventive protocols
- Where
- Pakistan
- Volunteers
- 344 people, healthy volunteers welcome
- Sponsor
- Forman Christian College, Pakistan
Focal Segmental Glomerulosclerosis, Minimal Change Disease
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis
- Trial name
- EPPIK (NCT05003986)
- Testing
- Sparsentan
- Where
- 47 sites in United States, Germany and 6 more
- Volunteers
- 67 people
- Sponsor
- Travere Therapeutics, Inc.
Nephrotic Syndrome in Children, Steroid-Dependent Nephrotic Syndrome
Reduce Immunosuppression With Atmp in NS ChildrEn
A phase II open-label, single arm study aimed to ascertain whether infusions of cord-blood mesenchymal stromal cells (CB-MSCs) allow to reduce or suspend the chronic immunosuppressive therapy (IS) in steroid-dependent nephrotic…
- Conditions
- Nephrotic Syndrome in Children, Steroid-Dependent Nephrotic Syndrome, Idiopathic Nephrotic Syndrome
- Trial name
- RACE (NCT04034316)
- Testing
- Cord-blood mesenchymal stromal cells
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Glomerular Disease, Minimal Change Disease
KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis
Glomerulonephritis (GN) generates an enormous individual and social economic burden. However, the therapeutic options are largely based on clinical and pathological parameters and the individual response to therapy or prognosis…
- Conditions
- Glomerular Disease, Minimal Change Disease, IgA Nephropathy, Membranous Nephropathy
- Trial name
- KORNERSTONE (NCT03929887)
- Testing
- Kidney Biopsy
- Where
- 6 sites in South Korea
- Volunteers
- 3,000 people
- Sponsor
- Seoul National University Hospital
Idiopathic Nephrotic Syndrome
A National Prospective Cohort of Patients With Idiopathic Nephrotic Syndrome Beginning in Childhood.
Pediatric idiopathic nephrotic syndrome (INS) is a rare disease for which the optimal therapeutic strategy has not yet been defined.
- Trial name
- PIN'SNP (NCT04207580)
- Testing
- Inclusion and follow up of pediatric patients with an idiopathic nephrotic syndrome,
- Where
- 48 sites in France, Reunion
- Volunteers
- 1,180 people
- Sponsor
- University Hospital, Limoges
Focal Segmental Glomerulosclerosis, Nephrotic Syndrome
Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney Failure
The investigators are trying to learn more about the cause of kidney diseases such as Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic syndrome by studying genetics.
- Conditions
- Focal Segmental Glomerulosclerosis, Nephrotic Syndrome, End Stage Renal Disease, Kidney Failure
- Trial name
- FSGS (NCT02194582)
- Where
- United States
- Volunteers
- 2,050 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Pain Management
MCID and PASS for Acute Pain and Quality of Recovery After Orthopedic Surgery
This study seeks to define what constitutes an MCID and a PASS in patients undergoing a variety of elective major orthopedic surgery.
- Trial name
- NCT04811209
- Testing
- 1.Baseline Measurements Before Surgery, 2.Intraoperative Anesthetic Management, 3.Postoperative Analgesic Management
- Where
- Canada
- Volunteers
- 300 people
- Sponsor
- University Health Network, Toronto
Gastroesophageal Reflux Disease
Diagnostic Value of Flexible Spectral Imaging Color Enhancement (FICE) Plus Probe-based Confocal Laser Endomicroscopy (pCLE) for Minimal Change Esophageal Reflux Disease (MERD) Diagnosis
Gastroesophageal reflux disease (GERD) patients without obvious mucosal break by endoscopy were examined by FICE, followed by confocal. Validity scores for MERD diagnosis were analyzed.
- Trial name
- NCT02336100
- Testing
- Endoscopy (FICE and pCLE)
- Where
- Thailand
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- King Chulalongkorn Memorial Hospital
Membranous Nephropathy, Minimal Change Disease (MCD)
Immunophenotyping Profiling in Patients With Primary Nephrotic Syndrome
Immunophenotyping profiling of patients with primary MN, primary FSGS and MCD. Evaluation of these immune cell subsets as possible biomarkers to track response to treatment or disease relapse.
- Conditions
- Membranous Nephropathy, Minimal Change Disease (MCD), Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- NCT07702981
- Testing
- Rituximab (MABTHERA® or RITUXAN®)., Corticosteroids (CS)
- Where
- Greece
- Volunteers
- 40 people
- Sponsor
- University Hospital, Ioannina
Minimal Change Disease (MCD), Focal Segmental Glomerulosclerosis (FSGS)
A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis
This is a phase II/III multicenter, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of BAT4406F injection in patients with Minimal Change Disease/Focal Segmental Glomerulosclerosis
- Trial name
- NCT07499700
- Testing
- BAT4406F
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Bio-Thera Solutions